Sugi Predict

Sugi Predict / Compounds / SCHEMBL7524646

SCHEMBL7524646

SCHEMBL7524646

CC(C)CCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.60
▸ NFE2L2 Q16236 1/20 0.60
▸ TLR9 Q9NR96 1/20 0.60
▸ ALDH1A1 P00352 5/20 0.58
▸ GLS O94925 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ CASP3 P42574 1/20 0.51
▸ MAOB P27338 3/20 0.51
▸ MAPT P10636 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ CYP1A2 P05177 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29596524 1.00 KEAP1 (0.60) KEAP1NFE2L2TLR9ALDH1A1GLS
SCHEMBL1787317 0.89 MAOB (0.56) MAOBCYP1A2CYP2C19
SCHEMBL15293799 0.87 MAOB (0.59) MAOBCYP1A2CYP2C19
SCHEMBL30242673 0.86 ALDH1A1 (0.59) ALDH1A1GLSCYP1A2CYP2C19
SCHEMBL28989527 0.86 ALDH1A1 (0.59) ALDH1A1GLSCYP1A2CYP2C19
SCHEMBL14560517 0.86 ALDH1A1 (0.59) ALDH1A1GLSCYP1A2CYP2C19
SCHEMBL10215924 0.86 ALDH1A1 (0.59) ALDH1A1GLSCYP1A2CYP2C19
SCHEMBL19746901 0.86 ALDH1A1 (0.50) KEAP1NFE2L2TLR9ALDH1A1GLS
SCHEMBL3469500 0.85 MAOB (0.60) MAOBCYP1A2CYP2C19
SCHEMBL20099096 0.85 MAOB (0.60) MAOBCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114349678-B Continuous industrial production method of N-alkyl-nitrophthalimide 珠海派锐尔新材料有限公司 2024-04-26 — — CN claimed
CN-114349678-A Continuous industrial production method of N-alkyl-nitrophthalimide 珠海派锐尔新材料有限公司 2022-04-15 — — CN claimed
CN-114349678-B Continuous industrial production method of N-alkyl-nitrophthalimide 珠海派锐尔新材料有限公司 2024-04-26 — — CN disclosed
WO-2023222762-A1 N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF UNIVERSITY OF ZURICH (CH) 2023-11-23 — — WO disclosed
CN-116903517-A Preparation method of 4-nitro-N-alkylphthalimide 广东优巨先进新材料股份有限公司 2023-10-20 — — CN disclosed
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2023-05-04 — — US disclosed
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2023-05-04 — — US disclosed
WO-2022263676-A1 POLYSUBSTITUTED 4-HYDROXYPYRIDINE AND 4-HYDROXYQUINOLINE DERIVATIVES AS GPR84 ANTAGONISTS UNIVERSITY OF COPENHAGEN (DK) 2022-12-22 — — WO disclosed
CN-114349678-A Continuous industrial production method of N-alkyl-nitrophthalimide 珠海派锐尔新材料有限公司 2022-04-15 — — CN disclosed
EP-3904882-A1 GRAPHENE CHANNEL MEMBER COMPRISING CADAVERINE OLFACTORY RECEPTOR AND SENSOR COMPRISING SAME Korea Research Institute of Bioscience and Biotechnology (KR) 2021-11-03 — — EP disclosed
US-20210301324-A1 METHOD FOR ANALYZING FUNCTIONAL SUBUNIT PAIR GENE OF T CELL RECEPTOR AND B CELL RECEPTOR REPERTOIRE GENESIS INCORPORATION (JP) 2021-09-30 — — US disclosed
US-8361753-B2 Phosphotriester-modified oligonucleotide primers for nucleic acid amplification TRILINK BIOTECHNOLOGIES, INC. (US) 2013-01-29 — — US disclosed
US-8361753-B2 Phosphotriester-modified oligonucleotide primers for nucleic acid amplification TRILINK BIOTECHNOLOGIES, INC. (US) 2013-01-29 — — US disclosed
US-20120202145-A1 RADIATION-SENSITIVE COLORED COMPOSITION, COLOR FILTER AND METHOD FOR PRODUCING THE SAME, SOLID STATE IMAGE DEVICE, AND LIQUID CRYSTAL DISPLAY APPARATUS FUJIFILM CORPORATION (JP) 2012-08-09 — — US disclosed
WO-2012012627-A1 METHOD OF PREVENTING OR TREATING VIRAL INFECTION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2012-01-26 — — WO disclosed
US-7595299-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2009-09-29 — — US disclosed
US-20070281308-A1 CHEMICALLY MODIFIED OLIGONUCLEOTIDE PRIMERS FOR NUCLEIC ACID AMPLIFICATION TRILINK BIOTECHNOLOGIES, LLC 2007-12-06 — — US disclosed
US-20070281308-A1 CHEMICALLY MODIFIED OLIGONUCLEOTIDE PRIMERS FOR NUCLEIC ACID AMPLIFICATION TRILINK BIOTECHNOLOGIES, LLC 2007-12-06 — — US disclosed
US-7169760-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2007-01-30 — — US disclosed
EP-1193547-A1 COLORED SPECTROZONAL SILVER-HALIDE PHOTOGRAPHIC MATERIAL Zakrytoe Aktsionernoe Obschestvo Ordena Trudovogo Krasnogo Znameni Nauchno-Proizvodstvennoe Obiedinenie "Fomos" (ZAO NPO... (RU) 2002-04-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281308-A1 CHEMICALLY MODIFIED OLIGONUCLEOTIDE PRIMERS FOR NUCLEIC ACID AMPLIFICATION POLRMT, POLI, POLM KEAP1 3440/4885NFE2L2 2825/4885TLR9 120/4885
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA G6PD, QDPR, FASN KEAP1 1570/4885NFE2L2 4510/4885TLR9 2540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.